Physician profile
Charles B Quick
NPI 1174527691
$6,574.63
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,190 · 2020: $411 · 2021: $241 · 2022: $1,787 · 2023: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.34 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,164.09 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,155.13 | 2019-2023 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,020.62 | 2019-2023 | Breztri, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $389.52 | 2022-2023 | Dupixent |
| Mylan Specialty L.P. | $304.49 | 2019-2023 | Yupelri |
| Insmed, INC. | $290.96 | 2019-2023 | Arikayce |
| Pfizer INC. | $244.58 | 2019-2023 | |
| Genzyme Corporation | $212.38 | 2022-2023 | |
| Genentech USA, INC. | $197.82 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $194.49 | 2020-2023 | Glassia |
| Sunovion Pharmaceuticals INC. | $174.37 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $155.81 | 2023 | Acthar |
| Philips North America LLC | $126.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $124.26 | 2019-2023 | |
| United Therapeutics Corporation | $112.33 | 2022-2023 | Tyvaso |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.05 | 2022-2023 | Tezspire |
| Pulmonx Corporation | $94.73 | 2019 | |
| Shire North American Group INC | $83.40 | 2019 | |
| Merck Sharp & Dohme LLC | $54.91 | 2019-2023 | |
| Grifols USA, LLC | $50.65 | 2023 | Prolastin-C Liquid |
| Circassia INC. | $44.57 | 2019 | |
| Abbvie INC. | $44.01 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $29.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.48 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $29.31 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.88 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $27.35 | 2019 | |
| Nabriva Therapeutics, Plc | $26.05 | 2020 | |
| La Jolla Pharmaceutical Company | $24.12 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.14 | 2019 | |
| Allergan, INC. | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.